{
  "pmcid": "PMC10786722",
  "pmid": "38216550",
  "title": "Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity",
  "overall_score": 0.1583013743824429,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 8,
        "items": [
          {
            "variant": "c.1679T>G",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "c.1679T>G",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant association with low DPD activity.",
              "Sentence": "Genotype c.1679T>G is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1679T>G",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13, rs55886062), c.1905+1G>A (DPYD*2A, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "Our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare DPYD genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "(DPYD*13",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "(DPYD*13",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant association with low DPD activity.",
              "Sentence": "Genotype c.1679T>G is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1679T>G",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13, rs55886062), c.1905+1G>A (DPYD*2A, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "Our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare DPYD genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs55886062)",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "rs55886062)",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant association with low DPD activity.",
              "Sentence": "Genotype c.1679T>G is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1679T>G",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13, rs55886062), c.1905+1G>A (DPYD*2A, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "Our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare DPYD genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "c.1905+1G>A",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "c.1905+1G>A",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant adverse drug reactions linked to this variant.",
              "Sentence": "Genotype c.1905+1G>A is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1905+1G>A",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "This is in agreement with results from sequencing data established in large distinct populations, which showed that the vast majority of variants among pharmacogenes are rare (MAF < 1%) or very rare (MAF \u2264 0.1%) and non-synonymous, with an estimated 30-40% of functional variability likely attributed to these rare variants.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "(DPYD*2A",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "(DPYD*2A",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant adverse drug reactions linked to this variant.",
              "Sentence": "Genotype c.1905+1G>A is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1905+1G>A",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "This is in agreement with results from sequencing data established in large distinct populations, which showed that the vast majority of variants among pharmacogenes are rare (MAF < 1%) or very rare (MAF \u2264 0.1%) and non-synonymous, with an estimated 30-40% of functional variability likely attributed to these rare variants.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs3918290)",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "rs3918290)",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant adverse drug reactions linked to this variant.",
              "Sentence": "Genotype c.1905+1G>A is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1905+1G>A",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "This is in agreement with results from sequencing data established in large distinct populations, which showed that the vast majority of variants among pharmacogenes are rare (MAF < 1%) or very rare (MAF \u2264 0.1%) and non-synonymous, with an estimated 30-40% of functional variability likely attributed to these rare variants.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "c.2846A>T",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "c.2846A>T",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Affects DPD activity and toxicity risk in fluoropyrimidine treatment.",
              "Sentence": "Genotype c.2846A>T is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.2846A>T",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "(rs67376798)",
            "gene": "DPYD",
            "drug": "fluoropyrimidine",
            "annotation": {
              "Variant/Haplotypes": "(rs67376798)",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Affects DPD activity and toxicity risk in fluoropyrimidine treatment.",
              "Sentence": "Genotype c.2846A>T is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.2846A>T",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 0,
        "unmatched_count": 3,
        "items": [
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452352260,
              "Variant/Haplotypes": "rs56038477",
              "Gene": "DPYD",
              "Drug(s)": null,
              "PMID": 38216550,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).\" NOTE: the HapB has two variants, and c.1129-5923C>G rs75017182 is the causative variant, a recent study has shown they are not in perfect LD in all populations [PMID: 38129972].",
              "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Assay type": "plasma dihydrouracil/uracil",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "activity of",
              "Gene/gene product": "DPYD",
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1452352260"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452352325,
              "Variant/Haplotypes": "rs1801160",
              "Gene": "DPYD",
              "Drug(s)": null,
              "PMID": 38216550,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "The association between common DPYD genetic variants (MAF \u2265 1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
              "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Assay type": "plasma dihydrouracil/uracil",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "activity of",
              "Gene/gene product": "DPYD",
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1452352325"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452352320,
              "Variant/Haplotypes": "rs2297595",
              "Gene": "DPYD",
              "Drug(s)": null,
              "PMID": 38216550,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "The association between common DPYD genetic variants (MAF \u2265 1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
              "Sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.",
              "Alleles": "CC + CT",
              "Specialty Population": null,
              "Assay type": "plasma dihydrouracil/uracil",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "activity of",
              "Gene/gene product": "DPYD",
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1452352320"
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 2,
        "items": [
          {
            "variant": "c.1905+1G>A",
            "gene": "DPYD",
            "drug": "5-fluorouracil",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "c.1905+1G>A",
              "Gene": "DPYD",
              "Drug(s)": "5-fluorouracil",
              "PMID": 38216550,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with this variant experienced severe toxicity during treatment with 5-fluorouracil.",
              "Sentence": "c.1905+1G>A (DPYD*2A) is associated with increased risk of severe toxicity when treated with 5-fluorouracil as compared to wild-type DPYD.",
              "Alleles": "",
              "Specialty Population": "",
              "Assay type": "Next Generation Sequencing",
              "Cell type": "plasma samples",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "risk of",
              "Gene/gene product": "DPD",
              "When treated with/exposed to/when assayed with": "",
              "Multiple drugs And/or": "",
              "Comparison Allele(s) or Genotype(s)": "wild-type DPYD",
              "Comparison Metabolizer types": "",
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "(DPYD*2A)",
            "gene": "DPYD",
            "drug": "5-fluorouracil",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "(DPYD*2A)",
              "Gene": "DPYD",
              "Drug(s)": "5-fluorouracil",
              "PMID": 38216550,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with this variant experienced severe toxicity during treatment with 5-fluorouracil.",
              "Sentence": "c.1905+1G>A (DPYD*2A) is associated with increased risk of severe toxicity when treated with 5-fluorouracil as compared to wild-type DPYD.",
              "Alleles": "",
              "Specialty Population": "",
              "Assay type": "Next Generation Sequencing",
              "Cell type": "plasma samples",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "risk of",
              "Gene/gene product": "DPD",
              "When treated with/exposed to/when assayed with": "",
              "Multiple drugs And/or": "",
              "Comparison Allele(s) or Genotype(s)": "wild-type DPYD",
              "Comparison Metabolizer types": "",
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.7915068719122146,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 3,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.6999883371240953,
            "annotation": {
              "Study Parameters ID": 1452352264,
              "Variant Annotation ID": 1452352260,
              "Study Type": null,
              "Study Cases": 855.0,
              "Study Controls": null,
              "Characteristics": "plasma dihydrouracil/uracil",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.05",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452352264,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452352260,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 855.0,
                "prediction": 628,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "patients with DPD deficiency identified by [U] and UH2/U ratio",
                "score": 0.8998017311096191,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "< 0.05",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6977555015507866,
            "annotation": {
              "Study Parameters ID": 1452352360,
              "Variant Annotation ID": 1452352325,
              "Study Type": null,
              "Study Cases": 1055.0,
              "Study Controls": null,
              "Characteristics": "plasma dihydrouracil/uracil",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452352360,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452352325,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 1055.0,
                "prediction": 2928,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "All patients (non-deficient DPD)",
                "score": 0.8618435263633728,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "< 0.01",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6974214105045095,
            "annotation": {
              "Study Parameters ID": 1452352324,
              "Variant Annotation ID": 1452352320,
              "Study Type": null,
              "Study Cases": 1265.0,
              "Study Controls": null,
              "Characteristics": "plasma dihydrouracil/uracil",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452352324,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452352320,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 1265.0,
                "prediction": 180,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "patients who may exhibit low DPD activity",
                "score": 0.8561639785766602,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "< 0.01",
                "prediction": "< 0.01",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 2,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 2972,
              "Study Controls": null,
              "Characteristics": "patients eligible for an uracil analog-based chemotherapy",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 580,
              "Study Controls": null,
              "Characteristics": "partial DPD deficiency (UH2/U plasma ratio \u2264 10)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.00001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}